Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model

Toxicology and Applied Pharmacology

Volumn 255, Issue 2, 2011, Pages 200-206

  Liu, Jun Yan ^a   Qiu, Hong ^b   Morisseau, Christophe ^a   Hwang, Sung Hee ^a   Tsai, Hsing Ju ^a   Ulu, Arzu ^a   Chiamvimonvat, Nipavan ^b   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hypotension; Lipopolysaccharide; Metabolic profiling; Metabolomics; Mice

Indexed keywords

EPOXIDE HYDROLASE; GAMMA INTERFERON; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXYLIPIN; TRICLOCARBAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; HYPOTENSION; INFLAMMATION; MOUSE; NONHUMAN; SYSTOLIC BLOOD PRESSURE; TIME;

ANIMALS; ANTI-INFECTIVE AGENTS; BLOOD PRESSURE; CARBANILIDES; CYTOKINES; EPOXIDE HYDROLASES; HUMANS; INFLAMMATION; KINETICS; MALE; MICE; MODELS, MOLECULAR; OXYLIPINS; RANDOM ALLOCATION;

ANIMALIA; MURINAE; MUS;

EID: 80051580523     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.06.017     Document Type: Article

References (61)

1. Ahn K.C., Zhao B., Chen J., Cherednichenko G., Sanmarti E., Denison M.S., Lasley B., Pessah I.N., Kultz D., Chang D.P.Y., Gee S.J., Hammock B.D. In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens. Environ Health Persp 2008, 116:1203-1210.
2. Birch C.G., Hiles R.A., Eichhold T.H., Jeffcoat A.R., Handy R.W., Hill J.M., Willis S.L., Hess T.R., Wall M.E. Biotransformation products of 3,4,4′-trichlorocarbanilide in rat, monkey, and man. Drug Metab Dispos 1978, 6:169-176.
3. Black J.G., Howes D., Rutherford T. Skin deposition and penetration of trichlorocarbanilide. Toxicology 1975, 3:253-264.
4. Borhan B., Mebrahtu T., Nazarian S., Kurth M.J., Hammock B.D. Improved radiolabeled substrates for soluble epoxide hydrolase. Analytical biochemistry 1995, 231:188-200.
5. Chen J.G., Ahn K.C., Gee N.A., Ahmed M.I., Duleba A.J., Zhao L., Gee S.J., Hammock B.D., Lasley B.L. Triclocarban enhances testosterone action: a new type of endocrine disruptor?. Endocrinology 2008, 149:1173-1179.
6. Demetrulias J., Corbin N., Northroot H. The hairless mouse as a model for quantitating skin deposition of 3,4,4′-trichlorocarbanilide in bar soap. Toxicol Lett 1984, 22:241-248.
7. Dhanasekaran A., Al-Saghir R., Lopez B., Zhu D.L., Gutterman D.D., Jacobs E.R., Medhora M. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol-Heart C 2006, 291:H517-H531.
8. Dinarello C.A. Proinflammatory cytokines. Chest 2000, 118:503-508.
9. Dixon M. Graphical determination of Km and Ki. Biochem J 1972, 129:197.
10. Gledhill W.E. Biodegradation of 3,4,4′-trichlorocarbanilide, TCC, in sewage and activated-sludge. Water Res 1975, 9:649-654.
11. Gomez G.A., Morisseau C., Hammock B.D., Christianson D.W. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry-Us 2004, 43:4716-4723.
12. Gomez G.A., Morisseau C., Hammock B.D., Christianson D.W. Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. Protein Sci 2006, 15:58-64.
13. Halden R.U., Paull D.H. Co-occurrence of triclocarban and triclosan in US water resources. Environ Sci Technol 2005, 39:1420-1426.
14. Heidler J., Sapkota A., Halden R.U. Partitioning, persistence, and accumulation in digested sludge of the topical antiseptic triclocarban during wastewater treatment. Environ Sci Technol 2006, 40:3634-3639.
15. Hiles R.A., Birch C.G. Absorption, excretion, and biotransformation of 3,4,4′-trichlorocarbanilide in humans. Drug Metab Dispos 1978, 6:177-183.
16. Hiles R.A., Caudill D., Birch C.G., Eichhold T. Metabolism and disposition of 3,4,4′-trichlorocarbanilide in the intact and bile duct-cannulated adult and in the newborn Rhesus-monkey (M. mulatta). Toxicol Appl Pharm 1978, 46:593-608.
17. Howes D., Black J.G. Percutaneous absorption of triclocarban in rat and man. Toxicology 1976, 6:67-76.
18. Hwang S.H., Tsai H.J., Liu J.Y., Morisseau C., Hammock B.D. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007, 50:3825-3840.
19. Jeffcoat A.R., Handy R.W., Francis M.T., Willis S., Wall M.E., Birch C.G., Hiles R.A. Metabolism and toxicity of halogenated carbanilides - biliary metabolites of 3,4,4′-trichlorocarbanilide and 3-trifluoromethyl-4,4′-dichlorocarbanilide in rat. Drug Metab Dispos 1977, 5:157-166.
20. Jones P.D., Tsai H.J., Do Z.N., Morisseau C., Hammock B.D. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett 2006, 16:5212-5216.
21. Jones P.D., Wolf N.M., Morisseau C., Whetstone P., Hock B., Hammock B.D. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Analytical biochemistry 2005, 343:66-75.
22. Jung O., Brandes R.P., Kim I.H., Schweda F., Schmidt R., Hammock B.D., Busse R., Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005, 45:759-765.
23. Larsen B.T., Gutterman D.D., Hatoum O.A. Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur J Clin Invest 2006, 36:293-300.
24. Larsen B.T., Miura H., Hatoum O.A., Campbell W.B., Hammock B.D., Zeldin D.C., Falck J.R., Gutterman D.D. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKCa channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol-Heart C 2006, 290:H491-H499.
25. Li N., Liu J.Y., Timofeyev V., Qiu H., Hwang S.H., Tuteja D., Lu L., Yang J., Mochida H., Low R., Hammock B.D., Chiamvimonvat N. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches. J Mol Cell Cardiol 2009, 47:835-845.
26. Liu J.Y., Park S.H., Morisseau C., Hwang S.H., Hammock B.D., Weiss R.H. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Molecular cancer therapeutics 2009, 8:2193-2203.
27. Liu J.Y., Tsai H.J., Hwang S.H., Jones P.D., Morisseau C., Hammock B.D. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol 2009, 156:284-296.
28. Liu J.Y., Yang J., Inceoglu B., Qiu H., Ulu A., Hwang S.H., Chiamvimonvat N., Hammock B.D. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochemical Pharmacology 2010, 79:880-887.
29. Ludat K., Lang J., Gahl G.M., Frei U., Jorres A. The production of pro-inflammatory cytokines (IL-6, IL-8) in human peritoneal fibroblasts is up-regulated following stimulation with IL-1-beta and or TNF-alpha. J Am Soc Nephrol 1994, 5:463.
30. McElroy N.R., Jurs P.C., Morisseau C., Hammock B.D. QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. J Med Chem 2003, 46:1066-1080.
31. Melgarejo E., Medina M.A., Sanchez-Jimenez F., Urdiales J.L. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell B 2009, 41:998-1001.
32. Michaelis U.R., Fisslthaler B., Barbosa-Sicard E., Falck J.R., Fleming I., Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 2005, 118:5489-5498.
33. Michaelis U.R., Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Therapeut 2006, 111:584-595.
34. Morisseau C., Goodrow M.H., Dowdy D., Zheng J., Greene J.F., Sanborn J.R., Hammock B.D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. P Natl Acad Sci USA 1999, 96:8849-8854.
35. Morisseau C., Hammock B.D. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annual Review of Pharmacology and Toxicology 2005, 45:311-333.
36. Morisseau C., Merzlikin O., Lin A., He G., Feng W., Padilla I., Denison M.S., Pessah I.N., Hammock B.D. Toxicology in the fast lane: application of high-throughput bioassays to detect modulation of key enzymes and receptors. Environ Health Persp 2009, 117:1867-1872.
37. Morisseau C., Schmelzer K., Pedersen T., Eiserich J., Pinkerton K., Imig J., Hammock B. Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition. Faseb J 2006, 20:A669.
38. Newman J.W., Morisseau C., Hammock B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Progress in lipid research 2005, 44:1-51.
39. Nithipatikom K., Moore J.M., Isbell M.A., Falck J.R., Gross G.J. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am J Physiol-Heart C 2006, 291:H537-H542.
40. Node K., Huo Y.Q., Ruan X.L., Yang B.C., Spiecker M., Ley K., Zeldin D.C., Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
41. Northroot H., Demetrulias J., Wester R., Maibach H., Corbin N. Deposition of 3,4,4′-trichlorocarbanilide on human-skin. Toxicol Lett 1984, 22:235-239.
42. Parrish A.R., Chen G., Burghardt R.C., Watanabe T., Morisseau C., Hammock B.D. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol Toxicol 2009, 25:217-225.
43. Pozzi A., Macias-Perez I., Abair T., Wei S.Z., Su Y., Zent R., Falck J.R., Capdevila J.H. Characterization of 5,6-and 8,9-epoxyeicosatrienoic acids (5,6-and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 2005, 280:27138-27146.
44. Roman D.P., Barnett E.H., Balske R.J. Cutaneous antiseptic activity of 3,4,4′-trichlorocarbanilide Proc Scientific Section of Toilet Goods Association 1957, 28:1213-1214.
45. Scharpf L.G., Hill I.D., Maibach H.I. Percutaneous penetration and disposition of triclocarban in man - body showering. Arch Environ Health 1975, 30:7-14.
46. Schebb N.H., Inceoglu B., Ahn K.C., Morisseau C., Gee S.J., Hammock B.D. Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effects. Environ Sci Technol 2011, Epub ahead of print.
47. Schmelzer K.R., Inceoglu B., Kubala L., Kim I.H., Jinks S.L., Eiserich J.P., Hammock B.D. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. P Natl Acad Sci USA 2006, 103:13646-13651.
48. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. P Natl Acad Sci USA 2005, 102:9772-9777.
49. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukocyte Biol 2004, 75:163-189.
50. Seubert J.M., Zeldin D.C., Nithipatikom K., Gross G.J. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostag Oth Lipid M 2007, 82:50-59.
51. Spector A.A., Fang X., Snyder G.D., Weintraub N.L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004, 43:55-90.
52. Wang Y., Wei X., Xiao X., Hui R.T., Card J.W., Carey M.A., Wang D.W., Zeldin D.C. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 2005, 314:522-532.
53. Warren J.T., Allen R., Carter D.E. Identification of metabolites of trichlorocarbanilide in rat. Drug Metab Dispos 1977, 6:38-44.
54. Webler A.C., Michaelis U.R., Popp R., Barbosa-Sicard E., Murugan A., Falck J.R., Fisslthaler B., Fleming I. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am J Physiol-Cell Ph 2008, 295:C1292-C1301.
55. Weinberg J.R., Boyle P., Meager A., Guz A. Lipopolysaccharide, tumor-necrosis-factor, and interleukin-1 interact to cause hypotension. J Lab Clin Med 1992, 120:205-211.
56. Whitcomb R., Chen D., Wang Y.X., Anandan S.K., Gless R., Webb H. AR9281, a soluble epoxide hydrolase inhibitor-efficacy in a DIO mouse model plus pharmacokinetics and pharmacodynamics in mice and men. Diabetes 2009, 58:A165.
57. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., Achong M.K. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998, 101:311-320.
58. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., Kim I.H., Tuteja D., Mateo R.K.P., Singapuri A., Davis B.B., Low R., Hammock B.D., Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. P Natl Acad Sci USA 2006, 103:18733-18738.
59. Yan G.J., Chen S.P., You B., Sun J.X. Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc Res 2008, 78:308-314.
60. Yang J., Schmelzer K., Georgi K., Hammock B.D. Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 2009, 81:8085-8093.
61. Ying G.G., Yu X.Y., Kookana R.S. Biological degradation of triclocarban and triclosan in a soil under aerobic and anaerobic conditions and comparison with environmental fate modelling. Environ Pollut 2007, 150:300-305.